Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Tomohito, Wakabayashi"'
Autor:
Iku Niinomi, Keiko Hosohata, Yasuhiro Mori, Yuki Yamaguchi, Tomohito Wakabayashi, Mayako Uchida, Kazunori Iwanaga
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 5, Iss 1, Pp 1-4 (2019)
Abstract Background Infliximab (IFX) has changed the management of many life-threatening immune-mediated diseases. The high cost of IFX and its patent expiry have led to pharmaceutical companies developing a biosimilar; however, its safety profile re
Externí odkaz:
https://doaj.org/article/1888db929ef94a9da5636907542e2c0d
Autor:
Tomohito Wakabayashi, Keiko Hosohata, Saki Oyama, Ayaka Inada, Iku Niinomi, Hiroko Kambara, Tatsuya Iida, Keiko Hasebe, Hiroyuki Matsuoka, Mayako Uchida, Etsuko Kumagai
Publikováno v:
Journal of International Medical Research, Vol 49 (2021)
Objectives Proton pump inhibitors (PPIs) are widely used for acid suppression therapy. Recently, PPI use was reported to be associated with chronic kidney disease (CKD); however, whether a low dose of PPIs is associated with CKD remains unknown. Meth
Externí odkaz:
https://doaj.org/article/76fd37616f2c4182a3c5468a3b3de44d
Autor:
Keiko Hosohata, Ayaka Inada, Saki Oyama, Takashi Doi, Iku Niinomi, Tomohito Wakabayashi, Mayako Uchida, Kazunori Iwanaga, Hiroyuki Matsuoka
Publikováno v:
Clinical Medicine Insights: Case Reports, Vol 13 (2020)
Adherence to medications is an important challenge while treating chronic disease such as resistant hypertension, which is defined as uncontrolled blood pressure (BP) despite treatment with more than 3 antihypertensive drugs to achieve targets. It is
Externí odkaz:
https://doaj.org/article/4d523a85529c4820b0f78ce814fc7295
Autor:
Iku, Niinomi, Saki, Oyama, Ayaka, Inada, Tomohito, Wakabayashi, Tatsuya, Iida, Hiroko, Kambara, Mayako, Uchida, Yukako, Sano, Keiko, Hosohata
Publikováno v:
Cureus.
Cyclosporine is widely used to prevent allograft rejection after transplantation. The purpose of this study was to clarify the adverse events profiles associated with cyclosporine in transplant patients using a spontaneous reporting system database.R
Autor:
Iku Niinomi, Saki Oyama, Ayaka Inada, Tomohito Wakabayashi, Toshinori Hirai, Hiroko Kambara, Tatsuya Iida, Mayako Uchida, Yukako Sano, Keiko Hosohata
Publikováno v:
International journal of clinical pharmacology and therapeutics. 60(9)
Juvenile idiopathic arthritis (JIA) is a systemic inflammatory disease of childhood onset. The purpose of this study was to clarify the frequency of adverse events caused by drugs used in JIA treatment and characterize their safety profiles using a s
Autor:
Tomohito Wakabayashi, Iku Niinomi, Ayaka Inada, Sayaka Ueno, Keiko Hosohata, Kazunori Iwanaga, Saki Oyama, Takahiro Nakatsuji, Toshinori Hirai, Hiroko Kambara
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 59:372-377
Introduction The development of new xanthine oxidase (XO) inhibitors, such as febuxostat and topiroxostat, could offer an alternative to treatment with allopurinol. The purpose of this study was to compare safety profiles of new XO inhibitors with al
Autor:
Saki Oyama, Sayaka Ueno, Keiko Hosohata, Tatsuya Iida, Takahiro Nakatsuji, Hiroko Kambara, Kazunori Iwanaga, Ayaka Inada, Mayako Uchida, Tomohito Wakabayashi
Publikováno v:
Therapeutics and Clinical Risk Management. 16:741-747
Introduction Concerns over safety profiles of tumor necrosis factor (TNF)-alfa inhibitors have been raised. The purpose of this study was to clarify the adverse events associated with TNF-alfa inhibitors using a spontaneous reporting system database.
Publikováno v:
International journal of clinical pharmacology and therapeutics. 59(12)
Objective The calcineurin inhibitor tacrolimus has been widely used to prevent allograft rejection after transplantation. The purpose of this study was to clarify the adverse events associated with tacrolimus in solid organ transplantation using a sp
Autor:
Tomohito Wakabayashi, Iku Niinomi, Mayako Uchida, Keiko Hosohata, Yuki Yamaguchi, Kazunori Iwanaga, Yasuhiro Mori
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 5, Iss 1, Pp 1-4 (2019)
Journal of Pharmaceutical Health Care and Sciences
Journal of Pharmaceutical Health Care and Sciences
Background Infliximab (IFX) has changed the management of many life-threatening immune-mediated diseases. The high cost of IFX and its patent expiry have led to pharmaceutical companies developing a biosimilar; however, its safety profile remains unk
Publikováno v:
Clinical Drug Investigation. 39:665-670
The development of new oral anticoagulants (NOACs) has led to an alternative to treatment with warfarin. However, real-world data on comparing safety profiles of NOACs and warfarin are insufficient. The purpose of this study was to compare safety pro